TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05357846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg, IV (in the vein) on day 1 and day 22

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative radiotherapy
Description: External radiation with a total dose of 40.0 or 45.0 Gy is given in 20 fractions,5 fractions a week.
Study: NCT05662787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular Lithotripsy
Description: Enhancing percutaneous transluminal angioplasty by utilizing delivery of IVL to disrupt calcium in above the knee lesions prior to full balloon dilatation at low pressures
Study: NCT06028243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Information stage
Description: The researchers provided the intervention group participants with online training in healthy living awareness to prevent osteoporosis (400 minutes and two days). They held the training at all participants' convenience outside the class hours. The training consisted of four sections: (1) osteoporosis and diagnosis-treatment methods, (2) current approaches to the prevention of osteoporosis, (3) osteoporosis and nutrition, and (4) osteoporosis and physical exercise. The researchers employed interactive teaching methods and consulted three experts to prepare PowerPoint presentations. At the end of the training, the researchers taught the intervention group participants how to fill out the healthy life diary, such as calculating daily calcium intake. The researchers texted the intervention group participants all training videos on WhatsApp to allow them to watch them again.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Motivation stage
Description: The researchers regularly texted (WhatsApp) spot and reminder notifications concerning the prevention of osteoporosis. They asked them to assess the health behaviors they recorded in their diaries every week (daily calcium intake, weekly exercise duration, etc.) and the problems they experienced during the process. The researchers provided individual counseling to the participants by telephone (combating smoking, exercise barriers, food exchange for calcium sources, etc.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Behavior skills stage
Description: The target behavior skills were improved self-efficacy in doing weight-bearing exercises, taking calcium, and engaging in physical activity.
Study: NCT05617729

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline applied via swab
Description: sterile saline applied via swab

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine based gel
Description: gel applied via swab
Study: NCT06476847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP persistence
Description: A light touch, once off, low cost. lay counsellor led intervention, designed to focus decision making around HIV prevention addressing present bias, salience and over optimism. The intervention package consists of evidence informed reminders, commitment pledges and planning prompts.
Study: NCT05316272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised bone-loading exercise on 3 days per week for 36 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised bone-loading exercise on 3 days per week for 36 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised bone-loading exercise on 3 days per week for 36 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised bone-loading exercise on 3 days per week for 36 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA in pill form 50 milligrams taken daily for 36 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA in pill form 50 milligrams taken daily for 36 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA in pill form 50 milligrams taken daily for 36 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA in pill form 50 milligrams taken daily for 36 weeks
Study: NCT05452174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine, sold under the brand name Remeron, is an atypical antidepressant, and as such is used primarily to treat depression.
Study: NCT04996004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontorpacept (TTI-621)
Description: Ontorpacept (TTI-621) will be administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontorpacept (TTI-621)
Description: Ontorpacept (TTI-621) will be administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontorpacept (TTI-621)
Description: Ontorpacept (TTI-621) will be administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontorpacept (TTI-621)
Description: Ontorpacept (TTI-621) will be administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75 mg/m\^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75 mg/m\^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75 mg/m\^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75 mg/m\^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.
Study: NCT05815550

Intervention type: DRUG
Intervention: PPI
Description: Use of PPI defined as PPI mentioned in the safety report
Study: NCT04300751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Active alcohol or placebo, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Active alcohol or placebo, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Active opioid agonist or placebo, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Active opioid agonist or placebo, administered orally
Study: NCT05751278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651
Description: ERBE 1.1mm flexible single-use cryoprobe with oversheath

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Jaw 4 Pulmonary Biopsy Forceps
Description: Radial Jaw 4 Pulmonary Biopsy Forceps Standard Capacity for 2mm endoscope
Study: NCT05846646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMSA101
Description: Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immune checkpoint inhibitor
Description: 1st infusion on Cycle 1 Day 2, and then thereafter as per product label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: 1st infusion on Cycle 1 Day 2, and then thereafter as per product label

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PULSAR
Description: 1st day of Cycles 1, 2 and 3.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PULSAR
Description: 1st day of Cycles 1, 2 and 3.
Study: NCT05357846

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Description: External radiation with a total dose of 40.0 or 45.0 Gy is given in 20 fractions,5 fractions a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 50mg/m2, IV (in the vein) on day 1,day 8,day 15 and day 22
Study: NCT05550090

Intervention type: DRUG
Intervention: Chemotherapy
Description: All patients were given 2 cycles of chemotherapy, including the chemotherapy recommended by the clinical treatment guidelines for advanced metastatic breast cancer, which can be combined with targeted or immune or endocrine therapy.
Study: NCT06133153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THIODERM ELATE
Description: Thiomer-crosslinked Hyaluronic Acid Dermal Filler with Lidocaine for Injection into Lips

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm Ultra 3
Description: BDDE-crosslinked Hyaluronic Acid Dermal Filler with Lidocaine for Injection into Lips
Study: NCT04224974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EASE-psy
Description: All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT).~-EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms.
Study: NCT05789069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFB200603
Description: Participants will be administered HFB200603 as described in the experimental arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFB200603
Description: Participants will be administered HFB200603 as described in the experimental arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFB200603
Description: Participants will be administered HFB200603 as described in the experimental arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFB200603
Description: Participants will be administered HFB200603 as described in the experimental arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will be administered tislelizumab as described in the experimental arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will be administered tislelizumab as described in the experimental arm.
Study: NCT05357846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50mg/m2, IV (in the vein) on day 1,day 8,day 15 and day 22

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 25mg/m2,IV DRIP on day 1,day 8,day 15 and day 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2,IV DRIP on day 1,day 8,day 15 and day 22

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: esophagectomy
Description: McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 6-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagectomy
Description: McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 6-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
Study: NCT06245642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Xiwujia granule + Guipi granule
Description: Experimental group: Basic treatment + compound Xiwujia granules + Guipi granules simulator orally for 6 weeks Positive drug control group: basic treatment + Guipi granule + compound Xiwujia granule simulant Koufu for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Compound Xiwujia granule + Guipi granule
Description: Experimental group: Basic treatment + compound Xiwujia granules + Guipi granules simulator orally for 6 weeks Positive drug control group: basic treatment + Guipi granule + compound Xiwujia granule simulant Koufu for 6 weeks
Study: NCT04844619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg/ml KDR2-2 suspension eyedrop
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 16mg/ml KDR2-2 suspension eyedrop
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization.
Study: NCT06271876

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: The subjects will perform deep inspirations against a threshold device with varying resistances

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The subjects will perform deep inspirations against a threshold device with varying resistances
Study: NCT05860582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]GB491
Description: A single 150mg dose of GB491 containing approximately 50 uCi of \[14C\]GB491.
Study: NCT04905459

Intervention type: DIAGNOSTIC_TEST
Intervention: ARDA software application
Description: Subject images will be sent to the investigational ARDA software
Study: NCT05526651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: true electroacupuncture
Description: the investigators use stainless steel acupuncture needle, disposable : Huanqiu® 0.25 x 0.40 mm Electroacupuncture device : Hwato-SDZ V®, continuous wave, 2 Hz, for 30 minutes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: the investigators use the same device like true electroacupuncture group, but the acupuncture needle not puncture on the skin and only attached.~electroacupuncture device, with no electrical stimulation
Study: NCT05334316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered intravenously or orally based on daily CRP values and CRP corticosteriod dosing algorithm
Study: NCT04873427

Intervention type: GENETIC
Intervention: clonal heterogeneity evaluation
Description: Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis

Intervention type: GENETIC
Intervention: clonal heterogeneity evaluation
Description: Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
Study: NCT06264128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TPAP
Description: TPAP is a form of CPAP therapy where the therapy pressure is reduced from the beginning of inhalation through mid or later exhalation. The CPAP therapy pressure is only present at the end of the expiratory phase.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP is a standard formal at home therapy for obstructive sleep apnea where a device attached via a facemask applies a constant pressure to a patient's lungs during sleep. It is the reference standard in this study.
Study: NCT05611827

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin LipoMicel (250 mg)
Description: Quercetin LipoMicel® soft-gels. Total dose of 250 mg of quercetin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin LipoMicel (500 mg)
Description: Quercetin LipoMicel® soft-gels. Total dose of 500 mg of quercetin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin LipoMicel (1000 mg)
Description: Quercetin LipoMicel® soft-gels. Total dose of 1000 mg of quercetin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Regular/standard Quercetin (500 mg)
Description: Total dose of 500 mg of quercetin
Study: NCT05704738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injection
Study: NCT06367088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Patients were assigned to receive 10 mg/kg cadonilimab intravenously Q3W in combination with chemotherapy. The chemotherapy regimen is chosen by the physician.
Study: NCT04893343

Intervention type: OTHER
Intervention: Antibiotic treatment
Description: Antibiotic treatment

Intervention type: OTHER
Intervention: No antibiotic treatment
Description: No antibiotic treatment
Study: NCT06002932

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: planed 2-stent strategy
Description: Procedure: planed 2-stent strategy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: provisional 1-stent plus DEB strategy
Description: Procedure: provisional 1-stent plus DEB strategy
Study: NCT04726085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin 150mg
Description: Patients will be randomized to either received perioperative indomethacin or ibuprofen at the time of their emergent cerclage placement for 24 hours following surgery. Patient will be followed up through our electronic medical record system to determine gestational latency to evaluate if ibuprofen is inferior to indomethacin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 2400mg
Description: Patients will be randomized to either received perioperative indomethacin or ibuprofen at the time of their emergent cerclage placement for 24 hours following surgery. Patient will be followed up through our electronic medical record system to determine gestational latency to evaluate if ibuprofen is inferior to indomethacin.
Study: NCT06333639

Intervention type: OTHER
Intervention: orthopaedic surgery
Description: usual procedures for an orthopaedic surgery
Study: NCT06050616

Intervention type: OTHER
Intervention: Mental health symptoms
Description: Symptoms of depression measured by the Patient Health Questionnaire -8.~Symptoms of generalised anxiety, obsessives compulsive disorder, attention deficit hyperactivity disorder, social phobia, specific phobia, agoraphobia, post-traumatic stress disorder, measured by the Development and Well-Being Assessment (DAWBA).~Harmful drinking measured by the Alcohol use disorders identification test.~Drug use measured by the European School Survey Project on Alcohol and Other Drugs (ESPAD).~Suicide risk measured by the the Mini International Neuropsychiatric Interview.

Intervention type: OTHER
Intervention: Mental health symptoms
Description: Symptoms of depression measured by the Patient Health Questionnaire -8.~Symptoms of generalised anxiety, obsessives compulsive disorder, attention deficit hyperactivity disorder, social phobia, specific phobia, agoraphobia, post-traumatic stress disorder, measured by the Development and Well-Being Assessment (DAWBA).~Harmful drinking measured by the Alcohol use disorders identification test.~Drug use measured by the European School Survey Project on Alcohol and Other Drugs (ESPAD).~Suicide risk measured by the the Mini International Neuropsychiatric Interview.

Intervention type: OTHER
Intervention: Mental health symptoms
Description: Symptoms of depression measured by the Patient Health Questionnaire -8.~Symptoms of generalised anxiety, obsessives compulsive disorder, attention deficit hyperactivity disorder, social phobia, specific phobia, agoraphobia, post-traumatic stress disorder, measured by the Development and Well-Being Assessment (DAWBA).~Harmful drinking measured by the Alcohol use disorders identification test.~Drug use measured by the European School Survey Project on Alcohol and Other Drugs (ESPAD).~Suicide risk measured by the the Mini International Neuropsychiatric Interview.

Intervention type: OTHER
Intervention: Mental health symptoms
Description: Symptoms of depression measured by the Patient Health Questionnaire -8.~Symptoms of generalised anxiety, obsessives compulsive disorder, attention deficit hyperactivity disorder, social phobia, specific phobia, agoraphobia, post-traumatic stress disorder, measured by the Development and Well-Being Assessment (DAWBA).~Harmful drinking measured by the Alcohol use disorders identification test.~Drug use measured by the European School Survey Project on Alcohol and Other Drugs (ESPAD).~Suicide risk measured by the the Mini International Neuropsychiatric Interview.
Study: NCT05071820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health U mobile application
Description: Health U mobile application delivers daily microlearning modules and the health coach interactions within the Health U application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: National Diabetes Prevention Program
Description: CDC recognized National DPP that follows a set curriculum with modules delivered over 12 months
Study: NCT06064968

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent bladder catheterization
Description: Intermittent bladder catheterization will be taught and performed by intervention group twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent bladder catheterization
Description: Intermittent bladder catheterization will be taught and performed by intervention group twice daily.
Study: NCT06240598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second Look Laparoscopy
Description: Second Look Laparoscopy (SLL)
Study: NCT04090177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEAM Wheels
Description: A 1-month, peer-led, eHealth training program (TEAM Wheels) for individuals transitioning to manual wheelchair use to improve satisfaction with activity participation and related rehabilitation outcomes.
Study: NCT04531826

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5-strand hamstring graft preparation
Description: Five-strand hamstring graft preparation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5-strand hamstring graft preparation
Description: Five-strand hamstring graft preparation